Angelique Linley
Adult Health · Fort Lauderdale, FLNPI 1912601121
Payments from drug & device makers
Across 283 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$748
- Johnson & Johnson$681
- Merck$494
- Novartis$308
- Seagen Inc.$279
- Adaptive Biotechnologies Corporation$272
- plus $4K from 53 others
What the payments were for
- Food & beverage$6,59592%
- Education$5588%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,153 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 20 | $434,389 |
| JakafiRuxolitinib Phosphate | 28 | $433,044 |
| PromactaEltrombopag Olamine | 13 | $392,264 |
| ImbruvicaIbrutinib | 22 | $351,757 |
| Lenalidomide | 25 | $334,732 |
| XtandiEnzalutamide | 21 | $289,801 |
| RevlimidLenalidomide | 16 | $287,477 |
| LenvimaLenvatinib Mesylate | 12 | $273,596 |
| CalquenceAcalabrutinib Maleate | 16 | $231,713 |
| IbrancePalbociclib | 11 | $173,936 |
| ErleadaApalutamide | 12 | $168,215 |
| VenclextaVenetoclax | 15 | $75,754 |
| ProcritEpoetin Alfa | 27 | $72,104 |
| EliquisApixaban | 29 | $23,676 |
| Exemestane | 21 | $2,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $114 | $434,38920 claims |
| Incyte CorporationJakafi | $163 | $433,04428 claims |
| NovartisPromacta | $308 | $392,26413 claims |
| Astellas Pharma US IncXtandi | $189 | $289,80121 claims |
| Bristol Myers SquibbRevlimid | $73 | $287,47716 claims |
| Eisai Inc.Lenvima | $238 | $273,59612 claims |
| Johnson & JohnsonErleada, Procrit | $681 | $240,31939 claims |
| AstraZenecaCalquence | $188 | $231,71316 claims |
| PfizerIbrance, Eliquis | $748 | $197,61140 claims |
| AbbVieVenclexta | $68 | $75,75415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.
Other adult health in Fort Lauderdale
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.